Welcome to our dedicated page for Vor Biopharma SEC filings (Ticker: VOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Vor Biopharma Inc. (Vor Bio) SEC filings page on Stock Titan provides streamlined access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Nasdaq Global Select Market issuer trading under the symbol VOR, Vor Bio reports on its clinical-stage biotechnology business focused on telitacicept, a dual BAFF/APRIL fusion protein being developed for serious autoimmune diseases.
Through this page, readers can review current and historical filings such as Forms 10‑K and 10‑Q for detailed discussions of risk factors, financial condition, and the status of telitacicept clinical programs, along with Form 8‑K reports describing material events. Recent 8‑K filings have covered topics including underwritten public offerings of common stock, a private placement with institutional investors, a reverse stock split, changes to equity incentive plans, and governance updates involving Board and executive appointments.
Vor Bio also uses 8‑K filings to furnish investor presentations and clinical data updates, for example webcasts and slide decks discussing late-breaking Phase 3 results for telitacicept in Sjögren’s disease and IgA nephropathy, as well as global development plans in generalized myasthenia gravis. Other filings, such as proxy statements (DEF 14A), describe stockholder proposals related to equity plans, warrant issuances, and capital structure changes.
On Stock Titan, these documents are complemented by AI-powered summaries that highlight key points from lengthy filings, helping users quickly understand how new financings, clinical milestones, or corporate actions may affect Vor Bio’s capital structure and development strategy. Investors can also locate information related to registered offerings on Form S‑3, at‑the‑market sales programs, and other registration statements referenced in the company’s 8‑K disclosures. This page is designed to make it easier to follow the regulatory record behind VOR, from financial reporting to telitacicept’s progress through late-stage development.
Vor Biopharma Inc. reported several changes to its Board of Directors. On August 25, 2025, director Joshua Resnick, M.D. resigned effective immediately, followed on August 26, 2025 by the immediate resignations of directors Matthew Patterson and David Lubner. The company states that each resignation was not due to any disagreement with the company, and the Board expressed appreciation for their years of service.
On August 27, 2025, the Board appointed Sarah Reed as an independent Class II director to fill the vacancy created by Dr. Resnick’s resignation, with a term running until the 2026 annual meeting of stockholders. Reed, age 61, is General Counsel of RA Capital Management, L.P. and has substantial legal and governance experience, including roles at Harvard Law School and the Harvard Yenching Institute. She will receive a $40,000 annual cash retainer and stock options to purchase 60,000 shares of common stock upon appointment, plus options for 30,000 shares at each future annual meeting starting in 2026, under the company’s standard non-employee director compensation policy.
Vor Biopharma Inc. filed an 8‑K reporting that its Board may implement a reverse stock split with a ratio anywhere between 1‑for‑5 and 1‑for‑30, with the final ratio to be determined at the Board's sole discretion. The filing includes a consent from Cooley LLP and notes that the cover page XBRL tags are embedded in the inline XBRL document. The report is dated August 27, 2025 and is signed by Jean‑Paul Kress, Chief Executive Officer.
Vor Biopharma's prospectus supplement describes an "at the market" offering through Stifel under which the company may sell up to $119,699,305 of additional common stock, in addition to 1,275,758 shares already sold for gross proceeds of approximately $5,300,695. The supplement discloses a license from RemeGen for telitacicept outside Greater China; telitacicept is approved in China for systemic lupus erythematosus, rheumatoid arthritis and generalized myasthenia gravis and a global Phase 3 trial in gMG is underway. Net proceeds are planned for working capital, capital expenditures and general corporate purposes, with possible acquisitions though none are currently planned. The filing incorporates the 2024 Form 10-K whose auditor's report contains an explanatory paragraph raising substantial doubt about Vor's ability to continue as a going concern. The supplement also describes S-3 registration rights for certain holders and smaller reporting company thresholds and exemptions.
Vor Biopharma reported a dramatic net loss of $1.606 billion for the six months ended June 30, 2025, driven primarily by a $1.299 billion non-cash increase in the fair value of newly issued warrant liabilities. The company held $200.6 million of cash, cash equivalents and marketable securities at June 30, 2025, and raised $174.4 million of net proceeds from a June 2025 private placement of PIPE warrants, which management says alleviated prior substantial doubt about near-term liquidity.
The company in-licensed telitacicept from RemeGen, paying a $45.0 million upfront cash fee and issuing RemeGen warrants initially valued at $177.4 million, and recorded a $222.6 million research and development charge as part of that acquisition. Vor also implemented a Restructuring Plan in May 2025, reducing headcount by 154 employees (about 99%) and recording $30.7 million of restructuring costs, leaving a remaining severance liability of $11.5 million at June 30, 2025. Total assets were $205.4 million and stockholders' deficit was $(1,505.7) million at period end.
Vor Biopharma Inc. (VOR) Form 144 disclosure shows a proposed sale of 18,382 common shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $36,407.39 and an approximate sale date of 08/11/2025 on NASDAQ. The filing records that these shares were acquired as restricted stock on 08/01/2025 (12,696 shares) and 08/06/2025 (5,686 shares).
The notice also lists multiple sales by Robert Ang in June–July 2025 totaling 1,134,988 shares with gross proceeds of about $2,544,405.10. Several issuer and filer identification fields (including issuer name and filer CIK) are left blank in the form.
Vor Biopharma’s August 25 2025 virtual special meeting asks holders to approve three material proposals:
- Issuance Proposal – authorize the full issuance of up to 1.02 billion common shares upon exercise of pre-funded and RemeGen warrants sold on 25 Jun 2025 for $175 million gross; warrants carry a $0.0001 exercise price and cannot be exercised until shareholder approval and an increase in authorized share count are effective.
- Reverse Stock Split – empower the Board to enact, any time within one year, a one-for-5 to one-for-30 split to lift the per-share price and expand unissued, unreserved shares, thereby preserving Nasdaq listing and providing headroom for the warrant shares and future corporate purposes.
- Equity Plan Amendment – add 25 million shares to the 2021 Equity Incentive Plan, reduce annual evergreen increases from 5 % to 4 % and extend the evergreen through 2035.
Support agreements covering ≈62.1 % of voting power commit to vote “FOR” all three items, virtually ensuring passage. Failure to approve the issuance would block warrant exercise and force repeat meetings every 90 days, consuming cash and delaying access to $175 million. Non-approval of the split could risk future Nasdaq bid-price compliance and limit share availability. Each proposal requires a simple majority of votes cast; broker non-votes and abstentions are not counted.
Vor Biopharma Inc. (VOR) filed a Form 144 indicating an intention to sell restricted shares under Rule 144.
- Securities for sale: 29,432 common shares.
- Proposed broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, NY.
- Proposed sale date: 08 / 04 / 2025 on NASDAQ.
- Aggregate market value of planned sale: $61,589.40.
- Shares outstanding: 124,959,520; proposed sale equals roughly 0.02 % of total.
- Acquisition details: Shares obtained on 08 / 04 / 2025 via exercise for cash.
No prior sales in the last three months were reported, and the filer certifies no undisclosed material adverse information. The filing is routine, signals limited insider liquidity, and does not materially alter VOR’s capital structure.
FAQ
What is the current stock price of Vor Biopharma (VOR)?
What is the market cap of Vor Biopharma (VOR)?
